Published in Cancer Weekly, November 25th, 2003
"Topotecan is an established therapy for the treatment of recurrent ovarian cancer and has demonstrated significant antitumor activity in both platinum-sensitive and platinum-resistant patient populations," scientists writing in the journal Gynecologic Oncology report.
"The main toxicity associated with topotecan when used in the standard 5-day dosing schedule is myelosuppression, which is generally predictable, reversible, noncumulative, and manageable. Comparative trials have shown that topotecan is as effective as paclitaxel and pegylated liposomal doxorubicin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.